| Nidogen-2: A new biomarker in colon cancer patients. | Nidogen-2: A new biomarker in colon cancer patients.
Kiziltan R, Cikman O, Algul S, Aydin MA, Kemik O. | 04/2/2022 |
| Nidogen-2 Maintains the Contractile Phenotype of Vascular Smooth Muscle Cells and Prevents Neointima Formation via Bridging Jagged1-Notch3 Signaling. | Nidogen-2 Maintains the Contractile Phenotype of Vascular Smooth Muscle Cells and Prevents Neointima Formation via Bridging Jagged1-Notch3 Signaling.
Mao C, Ma Z, Jia Y, Li W, Xie N, Zhao G, Ma B, Yu F, Sun J, Zhou Y, Cui Q, Fu Y, Kong W. | 01/1/2022 |
| A pilot proteomic study with a prospective cohort suspected to develop preeclampsia. | A pilot proteomic study with a prospective cohort suspected to develop preeclampsia.
Liu J, Liu X, Zhao S, Zheng Y, Chen L, Wang J, Zhan S, Hu S, Dong Y, Tang G, Lu Y, Zhai Y, Cao Z. | 10/16/2021 |
| Genome-Scale Analysis Identified NID2, SPARC, and MFAP2 as Prognosis Markers of Overall Survival in Gastric Cancer. | Genome-Scale Analysis Identified NID2, SPARC, and MFAP2 as Prognosis Markers of Overall Survival in Gastric Cancer.
Shan Z, Wang W, Tong Y, Zhang J., Free PMC Article | 06/5/2021 |
| Silencing NID2 by DNA Hypermethylation Promotes Lung Cancer. | Silencing NID2 by DNA Hypermethylation Promotes Lung Cancer.
Wang J, Zhao Y, Xu H, Ma J, Liang F, Zou Q, Lin F. | 04/3/2021 |
| Evaluation of NID2 promoter methylation for screening of Oral squamous cell carcinoma. | Evaluation of NID2 promoter methylation for screening of Oral squamous cell carcinoma.
Srisuttee R, Arayataweegool A, Mahattanasakul P, Tangjaturonrasme N, Kerekhanjanarong V, Keelawat S, Mutirangura A, Kitkumthorn N., Free PMC Article | 11/28/2020 |
| Our study demonstrates that up-regulated NID2 plays an important role in promoting the invasion and migration of gastric cancer cells and has a potential of being a novel biomarker for diagnosis, treatment and prognosis of gastric cancer in the future. | NID2 can serve as a potential prognosis prediction biomarker and promotes the invasion and migration of gastric cancer.
Yu ZH, Wang YM, Jiang YZ, Ma SJ, Zhong Q, Wan YY, Wang XW. | 03/7/2020 |
| Our results indicated that NID2, COL4A1 and COL4A2 could be the potential novel biomarkers for gastric cancer diagnosis prognosis and the promising therapeutic targets | Integrated bioinformatics analysis reveals novel key biomarkers and potential candidate small molecule drugs in gastric cancer.
Wu Q, Zhang B, Wang Z, Hu X, Sun Y, Xu R, Chen X, Wang Q, Ju F, Ren S, Zhang C, Qi F, Ma Q, Xue Q, Zhou YL. | 08/31/2019 |
| High NID2 methylation is associated with non-small cell lung cancer. | The more potential performance of nidogen 2 methylation by tissue or plasma DNA over brichoalveolar lavage DNA in diagnosis of nonsmall cell lung cancer.
Feng X, Xie X, Zheng B, Peng C, Zhou H, Qin J. | 10/27/2018 |
| the serum NID2 levels show significant elevation in the ESCC patients and those with relatively high serum NID2 levels ( 32.6 mu mu g/L) are significantly associated with poor survival outcome compared with those with very low serum NID2 levels (< < 20.0 mu mu g/L). | Elevated levels of serum nidogen-2 in esophageal squamous cell carcinoma.
Chai AWY, Cheung AKL, Dai W, Ko JMY, Lee NPY, Chan KT, Law SY, Lung ML. | 09/1/2018 |
| Addition of a TWIST1/NID2-based DNA methylation assay adds diagnostic value to urine cytology and the model is sensitive to the classification of equivocal cytology. | Urinary NID2 and TWIST1 methylation to augment conventional urine cytology for the detection of bladder cancer.
Fantony JJ, Longo TA, Gopalakrishna A, Owusu R, Lance RS, Foo WC, Inman BA, Abern MR. | 03/3/2018 |
| Promoter methylation of NID2 was significantly higher in nasopharyngeal carcinoma and esophageal squamous cell carcinoma cells. NID2 suppresses the EGFR/Akt and integrin/FAK/PLCgamma metastasis-related pathways. | Metastasis-suppressing NID2, an epigenetically-silenced gene, in the pathogenesis of nasopharyngeal carcinoma and esophageal squamous cell carcinoma.
Chai AW, Cheung AK, Dai W, Ko JM, Ip JC, Chan KW, Kwong DL, Ng WT, Lee AW, Ngan RK, Yau CC, Tung SY, Lee VH, Lam AK, Pillai S, Law S, Lung ML., Free PMC Article | 02/24/2018 |
| Knockdown of nidogen-2 reduced SOX9 expression, whereas it up-regulated RUNX2 expression | Laminins and Nidogens in the Pericellular Matrix of Chondrocytes: Their Role in Osteoarthritis and Chondrogenic Differentiation.
Schminke B, Frese J, Bode C, Goldring MB, Miosge N. | 06/28/2016 |
| The cleavage of nidogen-1 and -2 is partially inhibited in human tumor samples. | Contribution of ADAMTS1 as a tumor suppressor gene in human breast carcinoma. Linking its tumor inhibitory properties to its proteolytic activity on nidogen-1 and nidogen-2.
Martino-Echarri E, Fernández-Rodríguez R, Rodríguez-Baena FJ, Barrientos-Durán A, Torres-Collado AX, Plaza-Calonge Mdel C, Amador-Cubero S, Cortés J, Reynolds LE, Hodivala-Dilke KM, Rodríguez-Manzaneque JC. | 03/8/2014 |
| combined methylation analysis of Twist homolog 1 and nidogen-2 genes may be a simple, noninvasive, sensitive, and specific method for detecting cancer cells in urine. | Hypermethylation of TWIST1 and NID2 in tumor tissues and voided urine in urinary bladder cancer patients.
Yegin Z, Gunes S, Buyukalpelli R. | 09/7/2013 |
| Decreased nidogen-2 expression is associated with hepatocellular carcinoma | Clinical significance of decreased nidogen-2 expression in the tumor tissue and serum of patients with hepatocellular carcinoma.
Cheng ZX, Huang XH, Wang Q, Chen JS, Zhang LJ, Chen XL. | 02/4/2012 |
| NID2 promoter hypermethylation is associated with oral cavity squamous cell carcinoma. | NID2 and HOXA9 promoter hypermethylation as biomarkers for prevention and early detection in oral cavity squamous cell carcinoma tissues and saliva.
Guerrero-Preston R, Soudry E, Acero J, Orera M, Moreno-López L, Macía-Colón G, Jaffe A, Berdasco M, Ili-Gangas C, Brebi-Mieville P, Fu Y, Engstrom C, Irizarry RA, Esteller M, Westra W, Koch W, Califano J, Sidransky D., Free PMC Article | 11/19/2011 |
| Nidogen-2 is a new biomarker for ovarian cancer which correlates closely with CA125. | Nidogen-2: a new serum biomarker for ovarian cancer.
Kuk C, Gunawardana CG, Soosaipillai A, Kobayashi H, Li L, Zheng Y, Diamandis EP., Free PMC Article | 05/31/2010 |
| nidogen-2 is equivalent to nidogen-1 in skin-organotypic coculture, and both can promote the development of a functional basement membrane zone | Lack of nidogen-1 and -2 prevents basement membrane assembly in skin-organotypic coculture.
Nischt R, Schmidt C, Mirancea N, Baranowsky A, Mokkapati S, Smyth N, Woenne EC, Stark HJ, Boukamp P, Breitkreutz D. | 01/21/2010 |
| short arm region of laminin-5 gamma2 chain: structure, mechanism of processing and binding to heparin, nidogen-1, fibulin-1 and fibulin-2 | Short arm region of laminin-5 gamma2 chain: structure, mechanism of processing and binding to heparin and proteins.
Sasaki T, Göhring W, Mann K, Brakebusch C, Yamada Y, Fässler R, Timpl R. | 01/21/2010 |
| found to be ubiquitous component of basement membrane zones underneath developing epithelia of most of the major organ systems; may participate in cell biological functions during human development | Nidogen-1 and nidogen-2 are found in basement membranes during human embryonic development.
Miosge N, Holzhausen S, Zelent C, Sprysch P, Herken R. | 01/21/2010 |
| Nidogen-2 compensation hypothesis to explain limited phenotype observed following elimination of nidogen-1 gene. | Evidence of nidogen-2 compensation for nidogen-1 deficiency in transgenic mice.
Miosge N, Sasaki T, Timpl R. | 01/21/2010 |
| CpG islands of both NID1 and NID2 genes are aberrantly methylated in human cancer samples and cancer cell lines. | Nidogen 1 and 2 gene promoters are aberrantly methylated in human gastrointestinal cancer.
Ulazzi L, Sabbioni S, Miotto E, Veronese A, Angusti A, Gafà R, Manfredini S, Farinati F, Sasaki T, Lanza G, Negrini M., Free PMC Article | 01/21/2010 |